

ESMO 2023 Industry Satellite Symposium

Considerations for Frontline Immunotherapy in NSCLC: A Case-Based Discussion

Monday, 23 October 2023 | 13:00–14:30 CEST

Salamanca Auditorium, Hall 3, IFEMA MADRID, Madrid, Spain

During this Industry Satellite Symposium, we aim to:

- Understand when monotherapy could be a suitable frontline treatment strategy for NSCLC
- Review optimal immunotherapy combination regimens for patients with NSCLC across the treatment landscape
- Explore treatment in difficult-to-treat patient subgroups

Faculty



**Dr. Martin Reck,
(Chair)**
Lung Clinic
Grosshansdorf,
Grosshansdorf,
Germany



**Dr. Delvys
Rodriguez-Abreu**
Hospital Universitario
Insular de Gran Canaria,
Las Palmas de Gran
Canaria, Spain



Dr. Lizza Hendriks
University Medical
Center,
Maastricht,
The Netherlands

Agenda

Timing	Session	Faculty
13:00–13:05	Welcome and Introduction	Martin Reck (Chair)
13:05–13:30	Mono vs Combination Therapy: Identifying if Less is More in Complex Patient Cases	Martin Reck (Germany)
13:30–13:55	Tailoring the Approach: Selecting the Optimal Immunotherapy Combination Regimen	Delvys Rodriguez-Abreu (Spain)
13:55–14:20	Navigating Difficult-to-Treat Populations: Additional Considerations for Immunotherapy	Lizza Hendriks (The Netherlands)
14:20–14:30	Discussion and Close	All faculty

sanofi **REGENERON**

This symposium is intended for healthcare professionals only.

This industry-sponsored symposium is organized and sponsored by Sanofi and Regeneron on the occasion of ESMO 2023 (20–24 October 2023).

This is not a CME program. This non-promotional symposium sponsored by Sanofi and Regeneron will include discussion of investigational products and products that may not be approved by the regulatory agency in your own country.

The discussion is provided for medical and scientific purpose only. Viewers are cautioned to use their own professional judgement and consult the primary references, full prescribing information and/or any other appropriate sources prior to making clinical judgement for individual patients based on the content of the discussion.

MAT-GLB-2303239-V3.0; Date of approval: July 2023

